These include acute myeloid leukemia (AML) with defining genetic abnormalities (such as RUNX1::RUNX1T1 and CBFB::MYH11 fusion), chronic myeloid leukemia (CML) in blast crisis, myeloid/lymphoid neoplasms with eosinophilia and kinase gene fusions (such as FGFR1-rearranged myeloid/lymphoid neoplasms), therapy-related AML, and AML with myelodysplasia-related changes (AML-MR). This evidence concerns the gene CBFB and lymphoid neoplasm.